← Back to Screener
electroCore, Inc. Common Stock (ECOR)
Price$6.31
Favorite Metrics
Price vs S&P 500 (26W)19.31%
Price vs S&P 500 (4W)-5.20%
Market Capitalization$51.01M
All Metrics
Book Value / Share (Quarterly)$0.15
P/TBV (Annual)1.95x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)55.07%
Cash Flow / Share (Quarterly)$-1.03
Price vs S&P 500 (YTD)36.76%
Gross Margin (TTM)87.22%
Net Profit Margin (TTM)-43.60%
EPS (TTM)$-1.65
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-1.65
Revenue Growth (5Y)55.71%
EPS (Annual)$-1.65
ROI (Annual)-157.56%
Gross Margin (Annual)87.22%
Net Profit Margin (5Y Avg)-156.44%
Cash / Share (Quarterly)$1.45
Revenue Growth QoQ (YoY)31.18%
ROA (Last FY)-74.82%
Revenue Growth TTM (YoY)27.20%
EBITD / Share (TTM)$-1.56
ROE (5Y Avg)-137.89%
Operating Margin (TTM)-41.06%
Cash Flow / Share (Annual)$-1.03
P/B Ratio45.83x
P/B Ratio (Quarterly)35.20x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.58x
Net Interest Coverage (TTM)-46.82x
ROA (TTM)-79.04%
EPS Incl Extra (Annual)$-1.65
Current Ratio (Annual)1.38x
Quick Ratio (Quarterly)1.11x
3-Month Avg Trading Volume0.07M
52-Week Price Return4.82%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.84
P/S Ratio (Annual)1.59x
Asset Turnover (Annual)1.72x
52-Week High$8.64
Operating Margin (5Y Avg)-161.47%
EPS Excl Extra (Annual)$-1.65
Tangible BV CAGR (5Y)-11.91%
26-Week Price Return26.20%
Quick Ratio (Annual)1.11x
13-Week Price Return-7.07%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.38x
Enterprise Value$50.579
Revenue / Share Growth (5Y)22.91%
Asset Turnover (TTM)1.81x
Book Value / Share Growth (5Y)-37.81%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.48x
Pretax Margin (Annual)-43.59%
Cash / Share (Annual)$1.45
3-Month Return Std Dev88.14%
Gross Margin (5Y Avg)82.13%
Net Income / Employee (TTM)$-0
ROE (Last FY)-157.56%
Net Interest Coverage (Annual)-15.59x
EPS Basic Excl Extra (Annual)$-1.65
Receivables Turnover (TTM)26.76x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.65
Receivables Turnover (Annual)26.76x
ROI (TTM)-235.81%
P/S Ratio (TTM)1.59x
Pretax Margin (5Y Avg)-160.87%
Revenue / Share (Annual)$3.78
Tangible BV / Share (Annual)$3.60
Price vs S&P 500 (52W)-29.82%
Year-to-Date Return40.69%
5-Day Price Return-3.66%
EPS Normalized (Annual)$-1.65
ROA (5Y Avg)-75.91%
Net Profit Margin (Annual)-43.60%
Month-to-Date Return4.64%
Cash Flow / Share (TTM)$-3.91
EBITD / Share (Annual)$-1.55
Operating Margin (Annual)-41.06%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-136.59%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.65
P/TBV (Quarterly)3.02x
P/B Ratio (Annual)14.08x
Inventory Turnover (TTM)2.48x
Pretax Margin (TTM)-43.59%
Book Value / Share (Annual)$1.13
Price vs S&P 500 (13W)-9.45%
Beta0.67x
Revenue / Share (TTM)$3.61
ROE (TTM)-235.81%
52-Week Low$4.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.18
4.18
4.18
4.18
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ECORelectroCore, Inc. Common Stock | 1.59x | 55.71% | 87.22% | -41.06% | $6.31 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.00 |
MASIMasimo Corporation | 6.11x | 5.95% | 61.90% | 20.30% | $178.45 |
TMDXTransMedics Group, Inc. Common Stock | 6.41x | 88.21% | 59.92% | 17.93% | $113.13 |
LIVNLivaNova PLC Ordinary Shares | 2.59x | 8.24% | 68.04% | 14.09% | $65.81 |
ITGRInteger Holdings Corporation | 1.66x | 11.55% | 27.39% | 11.90% | $89.32 |
AXGNAxogen, Inc. Common Stock | 8.90x | 14.93% | 74.31% | -3.49% | $37.23 |
CNMDCONMED Corporation | 0.89x | 9.77% | 54.59% | 7.46% | $39.68 |
BLFSBioLife Solutions Inc. | 10.84x | 14.87% | 64.56% | -17.26% | $22.19 |
INMDInMode Ltd. Ordinary Shares | 2.51x | 12.45% | 78.54% | 23.05% | $14.57 |
CBLLCeriBell, Inc. Common Stock | 8.96x | — | 87.89% | -65.57% | $21.13 |
About
electroCore Inc develops and commercializes gammaCore, an FDA-cleared non-invasive vagus nerve stimulation device for treating neurological disorders. The platform is approved for the acute and preventive treatment of migraine and cluster headaches in adults, as well as additional headache indications. electroCore is a commercial-stage bioelectronic medicine company leveraging neuromodulation technology in the neurology market.